Epilepsy triggered by mefloquine in an adult traveler to Uganda

Federico Gobbi, Andrea Rossanese, Dora Buonfrate, Andrea Angheben, Chiara Postiglione, Zeno Bisoffi

Department of Tropical Diseases,Sacro Cuore-Don Calabria Hospital, 37024 Verona, Italy
Chiar Paiglione, Prevention Department, ULSS 20 Verona, 37122 Verona, Italy

Author contributions: Gobbi F wrote the manuscript; Rossanese A and Postiglione C managed the patient; Buonfrate D and Angheben A performed the literature search; Bisoffi Z revised the manuscript; all authors have read and approved the final version to be published.

Correspondence to: Federico Gobbi, MD, PhD, Department of Tropical Diseases, Sacro Cuore-Don Calabria Hospital, Via Don A Sempreboni 5, Negrar, 37024 Verona, Italy. federico.gobbi@sacrocuore.it
Telephone: +39-45-6013563 Fax: +39-45-6013694
Received: September 25, 2013 Revised: November 7, 2013 Accepted: December 12, 2013 Published online: January 16, 2014

Abstract
We report a case of a traveler who visited Uganda for 8 d, and took mefloquine one tablet/week for malaria prophylaxis. After the second dose, he suffered from two episodes of loss of consciousness with seizures, therefore mefloquine was discontinued. During the flight back after full recovery, seizures reoccurred while he was on board, he was disembarked in Addis Ababa and then transferred to Nairobi. After repatriation to Italy, he experienced four other similar episodes. The patient was still on full dose anticonvulsant therapy one year and a half after, as any attempt at reduced dose was unsuccessful. Currently, three agents (mefloquine, atovaquone/proguanil, and doxycycline) are recommended for malaria chemoprophylaxis, with similar efficacy but different adverse event profiles, regimens, and prices. Considering that mefloquine is associated with a higher risk of neurologic and psychiatric adverse events than the alternative regimens, we suggest considering mefloquine as a second line choice after atovaquone/proguanil and doxycycline for short-term travelers.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

Key words: Mefloquine; Neuropsychiatric disorders; Epilepsy; Antimalarial chemoprophylaxis; Side effects

Core tip: We report a case of epilepsy due to mefloquine chemoprophylaxis. Considering that mefloquine is associated with a higher risk of neurologic and psychiatric adverse events than the alternative regimens, we suggest considering mefloquine as a second line choice after atovaquone/proguanil and doxycycline for short-term travelers.

Gobbi F, Rossanese A, Buonfrate D, Angheben A, Postiglione C, Bisoffi Z. Epilepsy triggered by mefloquine in an adult traveler to Uganda. World J Clin Cases 2014; 2(1): 12-15 Available from: URL: http://www.wjgnet.com/2307-8960/full/v2/i1/12.htm DOI: http://dx.doi.org/10.12998/wjcc.v2.i1.12

INTRODUCTION
According to most international guidelines[1-4], atovaquone/proguanil, doxycycline and mefloquine are all indicated as the first choice for the chemoprophylaxis of Plasmodium falciparum malaria. The efficacy of the three drugs seems to be comparable[5], but side effects and costs are different. Although a causal relationship between the drug intake and a severe side effect is usually difficult to demonstrate, it is well known that mefloquine is associated with a high risk of neurologic and psychiatric disorders (NPD). Weinke et al[6] estimated that one of 13000 travelers receiving mefloquine chemoprophylaxis suffers from serious central nervous system reactions. Barrett et al[7], in a postal and telephone survey, reported that 0.7% of...
travelers taking mefloquine had disabling NPD.

Adverse events related to mefloquine mostly occur in people with a past history of seizures or manic-depressive illness\[^8\], but in literature there are reports of cases of seizures in travelers, with no previous personal or family history of epilepsy, after taking mefloquine for treatment\[^9\] or prophylaxis\[^10\].

**CASE REPORT**

A 40-year-old Italian traveler visited Uganda for 8 d, and took mefloquine one tablet/week for malaria prophylaxis. His weight was 70 kg. His clinical history was unremarkable and he had no history of alcohol or tobacco abuse. He was vaccinated against yellow fever, hepatitis A and tetanus-diphtheria. Upon arrival in Kampala, after the second dose of mefloquine, he suffered from two subsequent episodes of grand mal seizure, therefore mefloquine was discontinued. The duration of the two episodes was about 5 min and the patient remained unconscious for 10 min. During the flight back after full recovery, seizures reoccurred while he was on board, so he was disembarked in Addis Ababa. One further episode occurred at the airport and another one upon urgent admission to the hospital. He was then transferred to Kenya Nairobi Hospital under suspicion of meningitis or cerebral malaria (both were later ruled out), where he started on phenytoin 100 mg twice a day.

After repatriation to Italy, two weeks after the first crisis, an electroencephalogram showed diffuse epileptiform abnormalities, while a brain-RM was negative. Then, he experienced four similar episodes and was treated with diazepam. Moreover, phenytoin was replaced by levetiracetam 500 mg twice a day. Levetiracetam was stopped after 6 mo, but subsequent seizure episodes required another course of anticonvulsivant prophylaxis, with sodium valproate 500 mg twice a day. The patient was still on full dose anticonvulsant therapy one year later, as any attempt at dose reduction was unsuccessful.

**DISCUSSION**

Currently, three drugs (mefloquine, atovaquone/proguanil, and doxycycline) are recommended for malaria chemoprophylaxis, with similar efficacy but different adverse event profiles, regimens, and prices\[^8\]. The choice of the different drugs depends on the levels of malaria transmission and presence of drug resistance in the destination area, on specific characteristics of the traveler (e.g., underlying health conditions, possible pregnancy, compliance to daily/weekly therapies), on the duration and purpose of travel and on costs. Jacquieroz et al\[^11\], in a review of drugs for preventing malaria in travelers, conclude that atovaquone-proguanil and doxycycline are the best tolerated agents and mefloquine is associated with adverse NPD. NPD includes two categories of symptoms: central and peripheral nervous system disorders (including headache, dizziness, vertigo, seizures) and psychiatric disorders (including major psychiatric disorders, anxiety and sleep disturbances)\[^12\]. Controlled studies have shown a significant excess of NPD in mefloquine users\[^13,15-16\]. Moreover, in a recent study, van Essen et al\[^17\] suggest that mefloquine disturbs motor learning skills. Considering NPD as potentially severe and dangerous adverse side effects and the availability of drugs with equivalent efficacy, the new Italian indications for malaria prophylaxis\[^18\] proposed mefloquine as a second line choice after atovaquone/proguanil and doxycycline for short-term travelers. However, mefloquine keeps playing a fundamental role for specific groups of travelers: pregnant and breastfeeding women, long-term travelers, adults and children visiting friends and relatives (VFR)\[^19\]. Travelling to malaria endemic areas during pregnancy is contraindicated because this disease is an important cause of stillbirth, spontaneous abortion or maternal death\[^20\]. However, for pregnant women who cannot defer their travel (mostly VFR), mefloquine is the only option, as doxycycline is contraindicated in pregnancy and, although proguanil is considered safe and no teratogenicity has been observed in animal studies using atovaquone, there are no sufficient data about safety of atovaquone/proguanil. In fact, mefloquine has been proved to be safe in the first trimester: according to Schlagenhaufer et al\[^21\], birth defect prevalence and fetal loss after mefloquine exposure in pregnancy were comparable in prospectively monitored cases to background rates. For long-term travelers (nonimmunized travelers who visit malaria endemic areas for a period of six mo or longer), malaria chemoprophylaxis is controversial. Although the risk of malaria increases with longer stays, the adherence to chemoprophylaxis decreases over time. Steffen et al\[^22\] reported that compliance with chemoprophylaxis was reported by 57.0% of travellers who spent less than 3 mo in Africa, compared with 29.2% who stayed for 3-12 mo. In case chemoprophylaxis is recommended, mefloquine, if well tolerated, remains a good option in alternative to doxycycline: the weekly dose facilitates a good adherence. Long-term atovaquone/proguanil is now registered in Italy, but a long-term chemoprophylaxis is too expensive. van Riemdijk et al\[^16\] found that NPD occurred more frequently in females and were more common in first-time users. Usually females weigh less than males, so we suggest to modulate the mefloquine dosage by body weight (i.e., people weighing between 40 and 60 kg should take 75% of the tablet)\[^4\]. For a traveler who takes mefloquine for the first time, it is advisable to start chemoprophylaxis 3 wk before travelling, because adverse effects usually appear at the first dose. Lobel et al\[^23\] found that the frequency of these events declined with the increasing duration of prophylaxis. Travelers who have taken mefloquine before and had no NPD can usually take this drug again. For many VFR families,
who stay long in high-risk areas, mefloquine represents a good option because of its low cost and weekly administration. Moreover, mefloquine is effective and well tolerated in children weighing < 20 kg. Considering that mefloquine is often the only drug that can be prescribed for young children VFR, because doxycycline is contraindicated in children < 8 years and atovaquone/proguanil is generally too expensive, mefloquine is considered the best option for VFR families.

In conclusion, we suggest considering mefloquine as a second choice for short-term (less than one mo) travelers; however, mefloquine remains a good option, in alternative to doxycycline, for long-term travelers and the first choice for pregnant women and VFR families.

COMMENTS

Case characteristics
Grand mal seizures after taking mefloquine for malaria prophylaxis.

Clinical diagnosis
The duration of each of the two episodes of grand mal seizures was about 5 min and the patient remained unconscious for 10 min.

Differential diagnosis
Epilepsy due to other causes.

Imaging diagnosis
Electroencephalogram showed diffuse epileptiform abnormalities, while a brain-RM was negative.

Treatment
The patient was treated with phenytoin 100 mg twice a day, then with levetiracetam 500 mg twice a day, and then with sodium valproate 500 mg twice a day.

Related reports
Adverse events related to mefloquine mostly occur in people with a past history of seizures or manic-depressive illness, but in literature there are also reports of cases of seizures in travelers who had no previous personal or family history of epilepsy, after taking mefloquine for treatment or prophylaxis.

Experiences and lessons
Authors suggest considering mefloquine as a second choice for short-term (less than one mo) travelers; however, mefloquine remains a good option, in alternative to doxycycline, for long-term travelers and the first choice for pregnant women and visiting relatives and families.

Peer review
This article highlights possible severe side effects of mefloquine and suggests to consider other drugs as a first choice for malaria chemoprophylaxis.

REFERENCES

1 World Health Organization. International Travel and Health. Available from: URL: http://www.who.int/ith

2 Centers for Disease Control and Prevention. Health Information for International Travel 2012. The yellow book. Available from: URL: http://www.cdc.gov/yellowbook

3 Laloo DG, Shingadia D, Passvol G, Chiiodini PL, Whitty CJ, Beeching NJ, Hill DR, Warrell DA, Bannister BA. UK malaria treatment guidelines. J Infect 2007; 54: 111-121

4 Deutsche Gesellschaft für Tropenmedizin und Internationale Gesundheit (DTG). Empfehlungen zur Malaravorbeugung. Available from: URL: http://www.dtg.org

5 Schlagenhaus P, Tschopp A, Johnson R, Nothdurft HD, Beck B, Schwart E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R. Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ 2003; 327: 1078 [PMID: 14604928 DOI: 10.1136/bmj.327.7423.1078]

6 Weinke T, Trautmann M, Held T, Weber G, Eichenlaub D, Fleischer K, Kern W, Pohle HD. Neuropsychiatric side effects after the use of mefloquine. Am J Trop Med Hyg 1991; 45: 86-91 [PMID: 1867351]

7 Barrett PJ, Emmine PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine and proguanil as antimarial prophylaxis: postal and telephone survey of travellers. BMJ 1996; 313: 525-528 [PMID: 8789977]

8 Bem JL, Kerr L, Stuerchler D. Mefloquine prophylaxis: an overview of spontaneous reports of severe psychiatric reactions and convulsions. J Trop Med Hyg 1992; 95: 167-179 [PMID: 1597872]

9 Schiennmann R, Coulaud JP, Bouchaud O. Seizures after anti-malarial medication in previously healthy persons. J Travel Med 2000; 7: 155-156 [PMID: 11179047]

10 Pous E, Gascon J, Obach J, Corachan M. Mefloquine-induced grand mal seizure during malaria chemoprophylaxis in a non-epileptic subject. Trans R Soc Trop Med Hyg 1995; 89: 434 [PMID: 7570889]

11 Jacquieroz FA, Croft AM. Drugs for preventing malaria in travellers. Cochrane Database Syst Rev 2009; (4): CD006491 [PMID: 19821371 DOI: 10.1002/14651858.CD006491.pub2]

12 Schlagenhaus P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010; 9: 357 [PMID: 21143096 DOI: 10.1186/1475-2875-9-357]

13 Meier CR, Wilcock K, Jick SS. The risk of severe depression, psychosis or panic attacks with prophylactic antimalarials. Drug Saf 2004; 27: 203-213 [PMID: 14756582]

14 Overbosch D, Schiltshuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD, Toovey S, Knobloch J, Nothdurft HD, Shaw D, Roskell NS, Chulay JD. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clin Infect Dis 2001; 33: 1015-1021 [PMID: 11528574 DOI: 10.1086/322694]

15 van Riemsdijk MM, Durkenboom MC, Ditters JM, Ligthelm RJ, Overbosch D, Stricker BH. Atovaquone plus chloroguanide versus mefloquine for malaria prophylaxis: a focus on neuropsychiatric adverse events. Clin Pharmacol Ther 2002; 72: 294-301 [PMID: 12235450 DOI: 10.1067/mcp.2002.127113]

16 van Riemsdijk MM, Ditters JM, Sturkenboom MC, Tulen JH, Ligthelm RJ, Overbosch D, Stricker BH. Neuropsychiatric events during prophylactic use of mefloquine before travelling. Eur J Clin Pharmacol 2002; 58: 441-445 [PMID: 12242605 DOI: 10.1007/s00228-004-0942-z]

17 van Essen TA, van der Giessen RS, Koekkoek SK, Vanderwerf F, Zeeuw CI, van Genderen PJ, Overbosch D, de Jeu MT. Anti-malaria drug mefloquine induces motor learning deficits in humans. Front Neurosci 2010; 4: 191 [PMID: 21151372 DOI: 10.3389/fnins.2010.00191]

18 Bisoffi Z, Gobbi F, Calleri G. Mefloquine restrictions, anti-malarial drug safety and the new Italian recommendations for malaria prophylaxis. Travel Med Infect Dis 2013; Epub ahead of print [PMID: 24332760 DOI: 10.1016/j.tmaid.2013.09.009]

19 Dubey JP, Lindsay DS. Fatal Neospora caninum infection in kittens. J Parasitol 1989; 75: 148-151 [PMID: 2493087 DOI: 10.1125/cmr.000059-07]

20 Desai M, ter Kuile FO, Nosten F, McGeary R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis 2007; 7: 93-104 [PMID: 17251080 DOI: 10.1016/s1473-3099(07)70021-x]

21 Schlagenhaus P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, Boutros MS, Rhein HG, Adamcova M. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis 2012; 54: e124-e131 [PMID: 22046304 DOI: 10.1093/cid/cis129]
Campbell CC. Long-term malaria prophylaxis with weekly mefloquine. *Lancet* 1993; 341: 848-851 [PMID: 8096560]

Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Bansod S, Rhein HG. Use of mefloquine in children - a review of dosage, pharmacokinetics and tolerability data. *Malar J* 2011; 10: 292 [PMID: 21981927 DOI: 10.1186/1475-2875-10-292]

P- Reviewers: Cavanna AE, Juan DS  S- Editor: Gou SX  L- Editor: Ma JY  E- Editor: Wang CH
